Lv1
12 积分 2025-02-24 加入
KS05.5.A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA
8小时前
待确认
CTIM-04. MODULATION OF THE INTRATUMORAL IMMUNE MICROENVIRONMENT BY LOCAL THERAPY WITH NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA
8小时前
待确认
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial
9小时前
已完结
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
1天前
已完结
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
2天前
已完结
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
3天前
已完结
Advances in the molecular genetics of gliomas — implications for classification and therapy
3天前
已完结
EXTH-33. COMBATING TUMOR HETEROGENEITY IN GLIOBLASTOMA WITH A NOVEL CAR-BASED PLATFORM
3天前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
4天前
已完结
HER2-targeted therapies beyond breast cancer — an update
4天前
已完结
皖公网安备34019202002308
